Navigation Links
A*STAR partners Roche to develop new cancer therapeutics
Date:7/14/2014

SingaporeA*STAR's Bioprocessing Technology Institute (BTI) has entered into an agreement with one of the world's largest pharmaceutical company, Roche, to identify novel drug candidates for the detection and treatment of cancer. The partnership brings together BTI's capabilities in novel antibody discovery and Roche's expertise in developing monoclonal antibody (mAbs) therapeutics, opening up the possibility of improved treatment for cancer, a leading cause of death worldwide.

The collaboration makes use of BTI's discovery of a new mechanism where antibodies can directly target and destroy cancer cells, which has the potential for an entirely new class of cancer treatment. Cancer cells may be distinguished from normal cells by their elevated levels of sugar on the cell surface. The mAbs discovered and generated by BTI are able to recognise these sugar targets and allow more accurate identification of cancer cells as compared to traditional antibodies that only target proteins. mAbs generated by BTI are also unique in having a novel mechanism of action; they cause pores to form on the surface of cancer cells, leading to cell degradation and the eventual death of these diseased cells.

Dr Andre Choo, Principal Scientist at BTI and lead investigator for the project, said, "It is exciting to be able to generate a new class of mAbs that can specifically recognise sugars and lead to rapid death of diseased cells. This opens up new strategies to target and kill cancer cells."

Based on this discovery, scientists from BTI have developed a pipeline of mAbs for major cancers found in Singapore. The partnership with Roche will allow new diagnostic tests and cancer treatments to be developed more quickly and to be brought earlier to patient care. Such treatments could complement and augment existing cancer drugs and result in more effective and safer treatments for cancer patients.

Prof Lam Kong Peng, Executive Director of BTI, said, "This collaboration underscores the effectiveness of BTI's antibody research and allows us to leverage on Roche's expertise to develop novel antibody-based therapeutics. We are confident that this will be the start of a long and fruitful partnership that will not only benefit human health but also the biologics industry."

Dr. Juan-Carlos Lopez, Head of the Roche Pharma Research and Early Development Academic Relations and Collaborations, said: "Accessing external innovation through partnerships with public sector research institutes is crucial for identifying first-in-class or best-in-class opportunities. Bringing together the know-how of BTI and the expertise of Roche increases the chance of success in developing novel antibody-based therapeutics targeting both cancer and cancer stem cells which have the potential to revolutionize how we treat cancer."


'/>"/>

Contact: Vanessa Loh
vanessa_loh@a-star.edu.sg
Biomedical Sciences Institutes (BMSI)
Source:Eurekalert  

Related medicine news :

1. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
2. Fruit flies light the way for A*STAR scientists to pinpoint genetic changes that spell cancer
3. A*STAR scientists identify potential drug target for inflammatory diseases including cancers
4. Singapore scientists led by A*STARs GIS identify 4 mechanisms that contribute to gastric cancers
5. A*STAR scientists discover switch critical to wound healing
6. A*STAR scientist Alex Matter awarded prestigious Szent-Györgyi Prize for progress in cancer
7. A*STAR scientist wins European Molecular Biology Organization Young Investigator award
8. A*STAR scientists uncover potential drug target to nip cancer in the bud
9. A*STAR scientists bring to light mechanism of drug for infections
10. Women With Older Partners More Often Admitted to Nursing Homes
11. University of Houston Graduate College of Social Work announces partnership with MD Anderson
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A*STAR partners Roche to develop new cancer therapeutics
(Date:12/6/2016)... Maryland (PRWEB) , ... December 06, 2016 , ... ... announced the launch of a Kickstarter crowd funding campaign ( http://kck.st/2g3a1so ) for ... health active alerts and even taking an EKG from the watch while sharing ...
(Date:12/6/2016)... ... December 06, 2016 , ... Specialty ... newly updated International Audit Protocol Consortium (IAPC) EHS audit protocol for Great ... understand the scope of their EHS regulatory obligations and rapidly collect, share, archive, ...
(Date:12/5/2016)... ... ... What: Shriners Hospitals for Children, with the help of Dimension Data, will bring ... monitor and web-enabled camera. Santa visits with children through Dimension Data’s program to connect ... is where the video connection to the North Pole will stream. Much like children ...
(Date:12/5/2016)... ... December 05, 2016 , ... SyncDog, Inc., the leading ... magazine, a leading online tech news platform connecting technology innovators with news, experience, ... explores the state of enterprise mobility security today, and how the SyncDog SentinelSecure™ ...
(Date:12/5/2016)... ... December 05, 2016 , ... Progressive Laboratories™ is ... and glutathione to enhance production of nitric oxide (NO). , NitroGenesis Pro™ is ... produce NO twice as effectively and sustains NO blood levels twice as long ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... GAINESVILLE and BOCA RATON, ... The Florida Institute for the Commercialization of Public ... it has finalized a funding agreement SegAna, LLC, ... technology developed at University of Central Florida. The ... publicly-funded research, and bridges early funding gaps for ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 ... Market by Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, ... 2021" published by MarketsandMarkets, the market is projected to reach USD ... at a CAGR of 13.5% during the forecast period of 2016 ... ...
(Date:12/5/2016)... , Dec. 5, 2016   BIOTRONIK today ... study. The study evaluates the safety and feasibility of ... an office setting. BioMonitor 2 is an ... that is placed underneath a patient,s skin to help ... (fainting). Atrial fibrillation is a leading cause of stroke ...
Breaking Medicine Technology: